Monday, December 13, 2021

Indivior faces shareholder revolt over ex-chief’s bonus


Indivior faces the threat of a shareholder revolt over the drugmaker’s decision to maintain bonus payments for its British former chief executive, who was jailed last year in a case related to the US opioid crisis.

Shaun Thaxter. Photograph: handout

Shaun Thaxter, 53, was sentenced to six months in federal prison in the US state of Virginia last October and agreed to pay $600,000 (£432,000) in fines and forfeiture, after pleading guilty in June to federal charges related to Indivior’s Suboxone Film, used to help reduce withdrawal symptoms in recovering opioid addicts. He is due to be released on 10 May.

Two influential shareholder advisory groups – Institutional Shareholder Services (ISS) and Glass Lewis – have advised investors to vote against the company’s pay report at its annual meeting on Thursday. They have questioned why “malus and clawback provisions” have not been applied, which allow businesses to reduce or cancel bonus payments, or ask executives to pay back bonuses, in certain circumstances.

Thaxter’s case focused on his role when certain Indivior employees gave “false and misleading” information about the safety of the medicine in submissions to Massachusetts’ Medicaid programme. This led to the drug being prescribed to patients with children under six years old – rather than a rival non-opioid product.

In July, Indivior agreed to pay $600m to federal and state authorities to settle criminal and civil investigations related to the marketing of Suboxone which portrayed it as a safer drug than rival medicines, following a $1.4bn settlement agreed with its former parent company, Reckitt Benckiser.

The US government has clamped down on the opioid epidemic in recent years – largely caused by the pharmaceutical industry’s push to sell opioid painkillers – which has claimed about half a million lives in two decades.

ISS said Thaxter left the company with 1.1m shares outstanding under its long-term incentive plan (LTIP), which will vest in 2022 and 2023 and are worth £1.65m at the current share price.

ISS said: “As a lead executive of the business since 2009, Shaun Thaxter is ultimately accountable for the financial and reputational harm suffered by the company in connection with the mis-selling of Suboxone. This litigation had hung over the company for many years, and was material to the financial statements.

“In these circumstances, the company would at minimum be expected to apply the full weight of the malus provisions to cancel all outstanding incentive awards. There also would appear to be a clear case for an attempt at clawback of previous payments remitted to Thaxter.”

Indivior said the company’s remuneration committee “determined, based on Mr Thaxter’s leadership that produced years of positive operational performance, and the absence of any findings of personal wrongdoing or malfeasance, to allow Mr Thaxter to retain his outstanding LTIP awards”.

When he left last summer, Thaxter received $1.1m in lieu of salary and benefits, along with $66,484 for legal fees and $42,314 for unused holidays. He also has options over 921,461 shares..



Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...